Daniel Clayton, PA
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 295 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,361 and has fallen 52.0% since, to $653 in 2025. Among surgical clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 295 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- AbbVie$744
- Amgen$542
- Abbott$425
- Collegium Pharmaceutical, Inc.$309
- Teva Pharmaceuticals USA, Inc.$179
- plus $2K from 29 others
What the payments were for
- Travel & lodging$210%
- Food & beverage$4,922100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 73 | $1,104 |
| AbbVie | 52 | $744 |
| Amgen | 30 | $542 |
| Abbott | 30 | $425 |
| Collegium Pharmaceutical, Inc. | 15 | $309 |
| Teva Pharmaceuticals USA, Inc. | 9 | $179 |
| Pfizer | 9 | $178 |
| Biohaven Pharmaceuticals, Inc. | 2 | $140 |
| Merck | 7 | $112 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $109 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $106 |
| Medtronic | 5 | $100 |
| Valinor Pharma, LLC | 5 | $92 |
| Novartis | 5 | $90 |
| Azurity Pharmaceuticals, Inc. | 5 | $84 |
| Almatica Pharma LLC | 4 | $60 |
| Radius Health, Inc. | 3 | $50 |
| Eisai Inc. | 3 | $48 |
| Spinal Simplicity, LLC | 2 | $46 |
| GRT US Holding, Inc. | 2 | $45 |
| Vertos Medical, Inc. | 2 | $43 |
| Saluda Medical Americas, Inc. | 1 | $42 |
| Lilly USA, LLC | 2 | $39 |
| Relievant Medsystems, Inc. | 2 | $38 |
| Redhill Biopharma Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Nalu Medical, Inc. | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Acacia Pharma Inc | 1 | $18 |
| Virtus Pharmaceuticals LLC | 1 | $15 |
| Advanced Oxygen Therapy Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Hydrocision, Inc. | 1 | $13 |
| Nevro Corp. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$124
How this compares
$4,943 in reported general payments places this provider in the 90th percentile of 130 surgical providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MovantikNaloxegol Oxalate | 47 | $21,430 |
| Gabapentin | 865 | $10,893 |
| LinzessLinaclotide | 14 | $7,593 |
| Baclofen | 353 | $3,805 |
| Tizanidine Hcl | 503 | $3,458 |
| Celecoxib | 117 | $2,817 |
| Amitriptyline Hcl | 184 | $2,230 |
| Cyclobenzaprine Hcl | 237 | $1,890 |
| Methocarbamol | 99 | $1,171 |
| Lubiprostone | 17 | $1,128 |
| Hydroxyzine Hcl | 68 | $1,103 |
| Diclofenac Sodium | 48 | $870 |
| Chlorzoxazone | 12 | $806 |
| Meloxicam | 290 | $776 |
| Duloxetine Hcl | 56 | $688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $35 | $21,43047 claims |
| AbbVieLinzess | $744 | $7,59314 claims |
| Almatica Pharma LLCSertraline Hcl | $60 | $10015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 130 surgical providers in Louisiana.
Other surgical in Houma
- Courtney MoseleyShreveport$33K
- Jennifer PikerLafayette$11K
- Richard TubbsNew Orleans$9K
- Brandie HenryBaton Rouge$6K
- David SepulvedaGonzales$6K
- Jonathan FletcherBaton Rouge$5K
- Keri MorrisNew Orleans$5K
- Jamie WallaceAlexandria$5K
- Adam-Paul LanglinaisLafayette$5K
- Amanda KwanBaton Rouge$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.